191 related articles for article (PubMed ID: 37197660)
1. Sequential therapy with supercharged NK cells with either chemotherapy drug cisplatin or anti-PD-1 antibody decreases the tumor size and significantly enhances the NK function in Hu-BLT mice.
Kaur K; Chen PC; Ko MW; Mei A; Senjor E; Malarkannan S; Kos J; Jewett A
Front Immunol; 2023; 14():1132807. PubMed ID: 37197660
[TBL] [Abstract][Full Text] [Related]
2. Probiotic-Treated Super-Charged NK Cells Efficiently Clear Poorly Differentiated Pancreatic Tumors in Hu-BLT Mice.
Kaur K; Kozlowska AK; Topchyan P; Ko MW; Ohanian N; Chiang J; Cook J; Maung PO; Park SH; Cacalano N; Fang C; Jewett A
Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31878338
[No Abstract] [Full Text] [Related]
3. ADCC against MICA/B Is Mediated against Differentiated Oral and Pancreatic and Not Stem-Like/Poorly Differentiated Tumors by the NK Cells; Loss in Cancer Patients due to Down-Modulation of CD16 Receptor.
Kaur K; Safaie T; Ko MW; Wang Y; Jewett A
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33440654
[TBL] [Abstract][Full Text] [Related]
4. Super-charged NK cells inhibit growth and progression of stem-like/poorly differentiated oral tumors
Kaur K; Topchyan P; Kozlowska AK; Ohanian N; Chiang J; Maung PO; Park SH; Ko MW; Fang C; Nishimura I; Jewett A
Oncoimmunology; 2018; 7(5):e1426518. PubMed ID: 29721395
[TBL] [Abstract][Full Text] [Related]
5. Supercharged NK Cell-Based Immuotherapy in Humanized Bone Marrow Liver and Thymus (Hu-BLT) Mice Model of Oral, Pancreatic, Glioblastoma, Hepatic, Melanoma and Ovarian Cancers.
Kaur K; Jewett A
Crit Rev Immunol; 2023; 43(2):13-25. PubMed ID: 37938193
[TBL] [Abstract][Full Text] [Related]
6. Characterizing hepatocellular carcinoma stem markers and their corresponding susceptibility to NK-cell based immunotherapy.
Chiang J; Chen PC; Pham J; Nguyen CQ; Kaur K; Raman SS; Jewett A
Front Immunol; 2023; 14():1284669. PubMed ID: 37954598
[TBL] [Abstract][Full Text] [Related]
7. Differences in Tumor Growth and Differentiation in NSG and Humanized-BLT Mice; Analysis of Human vs. Humanized-BLT-Derived NK Expansion and Functions.
Kaur K; Jewett A
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612108
[TBL] [Abstract][Full Text] [Related]
8. NK cells shape pancreatic and oral tumor microenvironments; role in inhibition of tumor growth and metastasis.
Jewett A; Kos J; Fong Y; Ko MW; Safaei T; Perišić Nanut M; Kaur K
Semin Cancer Biol; 2018 Dec; 53():178-188. PubMed ID: 30081230
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
10. Adoptive transfer of osteoclast-expanded natural killer cells for immunotherapy targeting cancer stem-like cells in humanized mice.
Kozlowska AK; Kaur K; Topchyan P; Jewett A
Cancer Immunol Immunother; 2016 Jul; 65(7):835-45. PubMed ID: 27034236
[TBL] [Abstract][Full Text] [Related]
11. Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells.
Juliá EP; Amante A; Pampena MB; Mordoh J; Levy EM
Front Immunol; 2018; 9():2140. PubMed ID: 30294328
[TBL] [Abstract][Full Text] [Related]
12. Augmentation of IFN-γ by bone marrow derived immune cells in the presence of severe suppression of IFN-γ in gingivae induced by zoledronic acid and denosumab in Hu-BLT mice model of ONJ.
Kaur K; Sun Y; Kanayama K; Morinaga K; Hokugo A; Nishimura I; Jewett A
Front Endocrinol (Lausanne); 2023; 14():1111627. PubMed ID: 36742414
[TBL] [Abstract][Full Text] [Related]
13. Suppression of Gingival NK Cells in Precancerous and Cancerous Stages of Pancreatic Cancer in KC and BLT-Humanized Mice.
Kaur K; Chang HH; Cook J; Eibl G; Jewett A
Front Immunol; 2017; 8():1606. PubMed ID: 29255459
[TBL] [Abstract][Full Text] [Related]
14. Resistance to cytotoxicity and sustained release of interleukin-6 and interleukin-8 in the presence of decreased interferon-γ after differentiation of glioblastoma by human natural killer cells.
Kozlowska AK; Tseng HC; Kaur K; Topchyan P; Inagaki A; Bui VT; Kasahara N; Cacalano N; Jewett A
Cancer Immunol Immunother; 2016 Sep; 65(9):1085-97. PubMed ID: 27439500
[TBL] [Abstract][Full Text] [Related]
15. Enhancing NK cell-mediated cytotoxicity to cisplatin-resistant lung cancer cells via MEK/Erk signaling inhibition.
Yang L; Shen M; Xu LJ; Yang X; Tsai Y; Keng PC; Chen Y; Lee SO
Sci Rep; 2017 Aug; 7(1):7958. PubMed ID: 28801607
[TBL] [Abstract][Full Text] [Related]
16. Multiple Defects of Natural Killer Cells in Cancer Patients: Anarchy, Dysregulated Systemic Immunity, and Immunosuppression in Metastatic Cancer.
Jewett A; Kos J; Kaur K; Turnsek TL; Breznik B; Senjor E; Wong P; Nguyen KY; Ko MW
Crit Rev Immunol; 2020; 40(2):93-133. PubMed ID: 32749091
[TBL] [Abstract][Full Text] [Related]
17. Osteoclasts and Probiotics Mediate Significant Expansion, Functional Activation and Supercharging in NK, γδ T, and CD3+ T Cells: Use in Cancer Immunotherapy.
Kaur K; Jewett A
Cells; 2024 Jan; 13(3):. PubMed ID: 38334605
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels.
Xu L; Chen X; Shen M; Yang DR; Fang L; Weng G; Tsai Y; Keng PC; Chen Y; Lee SO
Mol Oncol; 2018 Mar; 12(3):269-286. PubMed ID: 28865178
[TBL] [Abstract][Full Text] [Related]
19. Differentiation by NK cells is a prerequisite for effective targeting of cancer stem cells/poorly differentiated tumors by chemopreventive and chemotherapeutic drugs.
Kozlowska AK; Topchyan P; Kaur K; Tseng HC; Teruel A; Hiraga T; Jewett A
J Cancer; 2017; 8(4):537-554. PubMed ID: 28367234
[TBL] [Abstract][Full Text] [Related]
20. Natural Killer Cells: Diverse Functions in Tumor Immunity and Defects in Pre-neoplastic and Neoplastic Stages of Tumorigenesis.
Jewett A; Kos J; Kaur K; Safaei T; Sutanto C; Chen W; Wong P; Namagerdi AK; Fang C; Fong Y; Ko MW
Mol Ther Oncolytics; 2020 Mar; 16():41-52. PubMed ID: 31930165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
